{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-21-000183","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.754008+00:00","generated_at":"2026-06-30T01:16:05.059611+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M","bullets":["Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.","CryoLife retains FDA costs through Dec 31, 2022; Baxter may assume after Jan 1, 2023.","Q2 2021 revenue $76.1M, up 42% GAAP vs Q2 2020 $53.8M; net loss ($2.2M) ($0.06/shr); non-GAAP net income $4.8M ($0.12/shr).","FY2021 revenue guidance $296-300M; Q3 2021 expected $71-73M, with PerClot minimal in H2 due to sale."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-21-000183","json":"https://secwatch.observer/filing/0000784199-21-000183.json","markdown":"https://secwatch.observer/filing/0000784199-21-000183.md","text":"https://secwatch.observer/filing/0000784199-21-000183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/0000784199-21-000183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/cry-20210729x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:16:05.059611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}